RCG
LTRN icon

Rock Creek Group’s Lantern Pharma LTRN Stock Holding History

Rock Creek Group’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,906
Closed -$210K – 237
2020
Q4 		$210K Sell
10,906
-400
-4% -$6.91K 0.09% 130
2020
Q3 		$213K Buy
+11,306
New +$164K 0.11% 136

Other funds holding LTRN

CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rock Creek Group's LTRN Position: Q1 2021 in Review

Rock Creek Group sold out of Lantern Pharma (LTRN) in Q1 2021, closing a stake of 10,906 shares — an estimated $210K sold.

Rock Creek Group first reported a position in LTRN in Q3 2020 and held it in 2 quarters. The position peaked at $213K in Q3 2020. 24 funds tracked by Wall St. Rank hold LTRN as of Q1 2021.

  • Rock Creek Group reported no remaining Lantern Pharma position as of Q1 2021 after selling out during the quarter.
  • Rock Creek Group sold 10,906 Lantern Pharma shares in Q1 2021, an estimated $210K.
  • Rock Creek Group first reported a position in Lantern Pharma in Q3 2020 and held it in 2 quarters.
  • Rock Creek Group's Lantern Pharma position peaked at $213K in Q3 2020.
  • 24 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2021.

Based on Rock Creek Group's 13F filing for Q1 2021, filed 14 May 2021.